Discover Your Statistical Match in the Retatrutide Clinical Trial
Ever wondered how you might have responded to Retatrutide based on the ground breaking Phase 2 trial results? Our Trial Twin tool matches your profile with synthetic participants modelled on the actual statistical distributions from the 338-participant study published in the New England Journal of Medicine.
The Phase 2 trial demonstrated unprecedented weight loss results, with participants achieving up to 24.2% body weight reduction over 48 weeks. This interactive tool uses your age range, starting weight, height, and gender to find your closest statistical match from the trial data, showing you:
- Your matched participant’s starting profile and assigned dose
- Week-by-week weight loss progression over the full 48-week trial period
- Actual pounds lost at key milestones throughout the journey
- Final percentage of body weight lost at trial completion
While individual results vary significantly and this tool is for educational purposes only, it provides a fascinating glimpse into the real-world efficacy demonstrated in the clinical trial. The data represents one of the most significant advances in obesity treatment, with Retatrutide’s triple agonist mechanism (targeting GLP-1, GIP, and glucagon receptors) showing superior results compared to existing medications.
Please Note: The participants shown are statistical representations based on published trial data, not actual individuals. This tool is designed for educational insight into clinical trial outcomes and should not be used as medical advice or to predict individual treatment results.
🔬 Find Your Retatrutide Trial Twin
Discover how someone with your profile performed in the Phase 2 clinical trial
Based on real data from 338 participants in the 48-week Retatrutide trial published in the New England Journal of Medicine.
Your Profile
Answer 4 quick questions to find your statistical match
Analysing 338 trial participants…
Your Trial Twin Found! 🎯
Participant:
Share Your Match:
This tool uses statistical modelling based on published aggregate trial data from the NEJM Phase 2 Retatrutide study.
Understanding the Phase 2 Trial Data
Trial Design & Statistical Outcomes
The Phase 2 trial evaluated three dose concentrations (4mg, 8mg, and 12mg) against placebo across 338 participants over 48 weeks. The statistical modeling in this tool reflects the published aggregate data distributions, providing insight into the research outcomes.
Key Statistical Findings:
- 12mg cohort: Mean weight reduction of 22.5% (≤24.2% in some participants)
- 8mg cohort: Mean weight reduction of 17.5%
- 4mg cohort: Mean weight reduction of 12.9%
- Placebo: Mean weight reduction of 2.1%
For comparison with other research compounds, see our detailed analysis: Retatrutide vs Semaglutide Research Comparison and Retatrutide vs Tirzepatide Research Comparison.
Mechanism of Action in Laboratory Studies
Retatrutide represents a novel triple agonist approach in peptide research, simultaneously targeting:
- GLP-1 receptors: Glucose-dependent insulin regulation
- GIP receptors: Incretin hormone pathway activation
- Glucagon receptors: Metabolic rate and lipid oxidation (unique to Retatrutide)
This triple mechanism differentiates it from dual agonist compounds currently being studied. The glucagon component appears to contribute to increased energy expenditure, as demonstrated in preclinical models.
Trial Timeline & Milestones
Weight Reduction Progression Pattern:
- Weeks 0-4: Initial response phase (2-3% reduction typical)
- Weeks 4-12: Rapid reduction phase (8-11% cumulative)
- Weeks 12-24: Steady progression (15-18% cumulative)
- Weeks 24-36: Continued effects (18-21% cumulative)
- Weeks 36-48: Plateau phase (final 1-3% reduction)
Reported Adverse Events in Trial Data
For research reference, the published trial reported these occurrence rates:
| Event Type | 4mg (%) | 8mg (%) | 12mg (%) |
|---|---|---|---|
| Gastrointestinal | 35 | 45 | 55 |
| Injection site reactions | 8 | 10 | 12 |
| Heart rate increase (>20 bpm) | 15 | 22 | 26 |
Current Research Status
Phase 3 Trials: Currently enrolling participants across multiple studies:
- TRIUMPH-1: Obesity without diabetes (n=2,400)
- TRIUMPH-2: Obesity with diabetes (n=1,800)
- TRIUMPH-3: Cardiovascular outcomes study
- Expected completion: 2025-2026
Research Applications & Laboratory Use
Retatrutide is currently available as a research compound for laboratory investigation. Studies utilizing this peptide focus on:
- Metabolic pathway research
- Receptor binding affinity studies
- Comparative analysis with other incretin mimetics
- Dose-response relationship investigations
Note: All research peptides from verified suppliers should include certificates of analysis (COA) confirming purity and composition. Standard research concentrations range from 5mg to 15mg per vial for laboratory applications.
Additional Research Tools
Explore our other research calculators and tools:
- Retatrutide Dosage Calculator – Calculate research dosing protocols
- Peptide Reconstitution Calculator – Determine dilution ratios
Scientific References
- Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine. 2023;389:514-526.
- ClinicalTrials.gov Identifier: NCT04881760 (Phase 2 Study)
Research Disclaimer: This tool and all information provided are for educational and research purposes only. The data presented reflects published clinical trial statistics and should not be interpreted as medical advice. All peptides discussed are for laboratory research use only and are not for human consumption. Always consult relevant scientific literature and follow proper laboratory protocols when conducting research.